Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022
For the nine months, sales was CAD 2.55 million compared to CAD 2.12 million a year ago. Revenue was CAD 24.05 million compared to CAD 10.79 million a year ago. Net loss was CAD 0.248025 million compared to CAD 2.66 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.1 a year ago. Diluted loss per share from continuing operations was CAD 0.1 compared to CAD 0.1 a year ago.